Impact of Diabetes and Weight Loss Drugs on Alcohol Consumption
Recently, some individuals taking diabetes and weight loss medications such as Ozempic, Wegovy, Zepbound, and Mounjaro have reported a decreased desire to consume substances other than food, including alcohol. These drugs appear to reduce the effects of substances like nicotine and alcohol, although scientists have yet to fully understand why.
New Study Offers Insights
A recent preliminary study published in Scientific Reports provides evidence on how these new medications may reduce alcohol consumption and the sensation of intoxication. The authors suggest that understanding the mechanism of these drugs throughout the entire body, not just the brain, could open new avenues for treating alcohol use disorder.
Alex DiFeliceantonio, a co-author of the study and a neuroscientist at Virginia Tech, states, “There is a lot of activity in the brain, but our paper points out that there is also potential activity in the gut. We need to consider both to fully understand how these drugs work to reduce the consumption of substances with abuse potential.”
Mechanism and Effects of the Drugs
These medications work by enhancing insulin secretion and making individuals feel full by mimicking the natural gut hormone GLP-1. Scientists agree that the primary way GLP-1 drugs cause weight loss is through their effect on satiety in the brain, making people feel full faster and ultimately eat smaller amounts.
However, the drugs also cause a physiological reaction in the gut: they slow the movement of food and liquids from the stomach to the small intestine, a process known as gastric emptying. DiFeliceantonio notes that people taking these medications “can’t eat much because the food stays in the stomach longer.”
Effect on Alcohol Consumption
These drugs delay gastric emptying, which means alcohol takes longer to reach the brain. DiFeliceantonio explains, “We know that slowing the arrival of any substance to the brain makes it less rewarding.”
In the study, researchers tested this hypothesis in their lab by offering alcoholic drinks to a group of participants taking GLP-1 drugs and another group not taking them. They observed that the group on the medication felt less intoxicated.
Study Challenges and Future Directions
The study faced several challenges, including a small sample size and the diversity of drugs used. Nevertheless, it is considered an initial step in understanding the impact of these drugs on alcohol consumption.
Carolina Haass-Koffler, an addiction researcher, points out that introducing GLP-1 drugs to a new population requires careful assessment of risks and benefits. Although there is some evidence suggesting the effectiveness of these drugs in reducing alcohol cravings, caution is advised when using them with individuals who have alcohol use disorders and are underweight.
Conclusion
Recent studies indicate that GLP-1 drugs may offer unexpected benefits in reducing alcohol consumption by altering gastric emptying and their effects on the brain. While these findings are promising, further research is needed to fully understand the impact of these medications on alcohol use disorders and other addictive behaviors.